NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $1.31M rose 62.8% year over year, ahead of the -18.5% change in trailing-twelve-month research & development. Sequentially, it rose 134.6% from the prior quarter. Over 3 fiscal years it compounded at -39.5% a year.
Context
- Research & development amounted to 308.3% of revenue in FY2025.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +62.8% holds above the trailing-twelve-month pace of -18.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 3.78M USD
- Year-over-year change
- -39.1%
- 4-year CAGR
- -34.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.78M | -39.1% |
| FY2024 | 2024-12-31 | 6.2M | -53.6% |
| FY2023 | 2023-12-31 | 13.37M | -21.5% |
| FY2022 | 2022-12-31 | 17.03M | -15.9% |
| FY2021 | 2021-12-31 | 20.26M | — |
Research & Development vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 research & development of $4.28M is the 8th highest of the 9 companies compared; the peer median is $27.08M.
- Its year-over-year change of -18.5% is the 4th highest of 9, against a peer median of -32.1%.
- Research & development amounts to 186.8% of revenue for NRXP, versus a peer median of 110.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.78M | -12.3% | -5.5% | 82.6% | |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $36.03M | +4.0% | -0.7% | 110.1% | |
| LTM Jun 2026 | $32.91M | -39.6% | -5.9% | 156.7% | |
| LTM Mar 2026 | $21.25M | -43.8% | +8527.1% | 6378.2% | |
| LTM Mar 2026 | $16.69M | -64.4% | -17.8% | — | |
| LTM Mar 2026 | $9.91M | -70.5% | -30.1% | — | |
| LTM Mar 2026 | $4.28M | -18.5% | -39.5% | 186.8% | |
| LTM Mar 2026 | $1.43M | -13.1% | +294.0% | 100.9% | |
| Peer median (excluding NRXP) | $27.08M | -32.1% | -3.1% | 110.1% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Cost of Revenue | 2K | 4K | 5K | 5K | 505K |
| Gross Profit | (2K) | (4K) | (5K) | (5K) | 720K |
| Gross Margin | — | — | — | — | 58.8% |
| Research & Development | 20.26M | 17.03M | 13.37M | 6.2M | 3.78M |
| Selling, General & Admin | 74.94M | 27.3M | 14.21M | 13.5M | 13.06M |
| Operating Expenses | 95.2M | 44.33M | 27.58M | 19.7M | 16.94M |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| EBITDA | (93.04M) | (39.75M) | (30.03M) | (24.04M) | (27.81M) |
| EBITDA Margin | — | — | — | — | -2270.0% |
| Operating Income | (95.2M) | (44.34M) | (27.59M) | (19.7M) | (16.22M) |
| Operating Margin | — | — | — | — | -1324.4% |
| Interest Income | 18 | 249K | 494K | 44K | 12K |
| Interest Expense | 18K | 0 | 120K | 1.08M | 671K |
| Other Income / Expenses | 2.14M | 4.58M | (2.56M) | (5.42M) | (12.4M) |
| Income Before Tax | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Pre-Tax Margin | — | — | — | — | -2336.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Net Margin | — | — | — | — | -2336.5% |
| EPS (Basic) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| EPS (Diluted) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| Weighted Avg Shares | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
| Weighted Avg Shares (Diluted) | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.